JUST RELEASED: Continued macroeconomic headwinds led to a 20% drop in pharma M&A deals from H1 2023 to H1 2024. What does this mean for the industry? Find out the top M&A and partnership deals in the #PharmaDeals H1 Review of 2024. https://bit.ly/3MHjuqO #MergersAndAcquisitions
IQVIA Global Market Insights
Pharmaceutical Manufacturing
Durham, North Carolina 19,742 followers
About us
Through our Gold Standard data and analytics, Global Market Insights supports pharmaceutical and life sciences organizations in measuring, managing and segmenting markets, finding and sizing opportunities and maximizing the return on investment across the pharmaceutical drug lifecycle worldwide.
- Website
-
https://www.iqvia.com
External link for IQVIA Global Market Insights
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Durham, North Carolina
Updates
-
As the prevalence of obesity-related comorbidities rises, the race for safe and effective treatments intensifies. Download our newest article by #PipelineLink #TrialLink to deep dive into the #obesity landscape and for the latest clinical trial insights and pipeline updates. https://bit.ly/47qRf9p #obesitytreatment #ObesityMedicine
-
Join the IQVIA Institute next Tuesday for a multi-stakeholder panel discussion on Hematologic Cancer Opportunities for Patient Equality (HOPE): Achieving equitable and timely access to hematological cancer therapies. This critical discussion will focus on actions and policies that are needed to overcome the key barriers that limit hematological cancer therapy access. 📅 17 September 2024 ⌚10:30 a.m. – 12:00 p.m. CET (Geneva) Confirmed speakers: 🎙️ Antonella Cardone 🎙️ Kathleen Gesy 🎙️ Richard Price 🎙️ Maciej Miłkowski Moderator: Murray Aitken Register here: https://bit.ly/3B0QPdQ. #IQVIAMIDAS
-
NEXT WEEK: Meet our #IQVIA #RegulatoryIntelligence team at #RAPS2024! Visit us at booth #530 to chat with our experts to help you overcoming your regulatory challenges and find out how we can support your business to help make work easier for you. See you there! https://bit.ly/3Zk3DGy #RAPSConvergence #Networking #Event
-
Oncology remains a powerhouse of innovation, with over 100 new cancer treatments expected to launch in the next five years. Download your copy of our latest white paper by authors Markus Gores and Stefan Lutzmayer for insights into novel therapeutic modalities and success factors for #oncology innovators. https://bit.ly/3ZgLLw8 #AnalyticsLink #IQVIAMIDAS #PharmaDeals
-
Want to simplify your #CMC processes and reduce errors? Improve collaboration across your team and reduce errors with our new CMC table, a centralized source of information, designed to support your #regulatory submissions. Request a demo https://lnkd.in/en5ieWfs or meet us at #RAPS2024
-
If you’re attending #CPHIMilan on October 9, join us for a deep dive into Oncology’s latest innovations. IQVIA expert Aurelio Arias will present ‘Exploring Emerging Innovations in Oncology”, where we will explore growth areas within Oncology, evaluate patient outcomes, discuss successful medicine launches, and delve into future clinical trials, manufacturing advancements, and off-patent opportunities. Don’t miss it! https://bit.ly/3Z85X3a #GlobalMarketInsights #OncologyInnovation #HealthcareAdvancements
-
A new era in Alzheimer’s treatment has begun! The USA’s approval of the anti-N3pG amyloid beta peptide monoclonal antibody in July 2024 provides a second treatment option for patients in the early stages of #AlzheimersDisease. Read this article for insights into this ground-breaking development. https://bit.ly/3XaG3t6 #PipelineLink #TrialLink #MonoclonalAntibodyAdvances
-
Antibody-drug conjugate (ADC) therapies are specialized chemotherapy agents that combine the target specificity of monoclonal antibody with cytotoxic agents that destroy malignant cells. These novel therapies have the ability to improve clinical outcomes in hematological cancer patients, but there are significant inequities in access to these drugs. IQVIA Institute analyzed the availability of these drugs in France, Poland, Australia, Canada, Ireland, Italy, Spain, Brazil, Bulgaria, Greece, Lithuania, and Romania. 🌍As of December 2023, almost all countries in this analysis have at least one ADC available, and Lithuania remains the only country in this analysis with no available ADC. 🌍France has the shortest average time to availability for ADCs with 324 days while Romania has the longest with 1,055 days. 🌍All other countries besides Romania, Bulgaria, Greece, and Spain have an average time to availability for ADCs that is lower compared to the average time to availability of hematological cancer drugs in general. This means it’s on the country to provide timely access to these innovative therapies. Learn more about access to hematologic drugs in various countries: https://bit.ly/3XrCO1B. #patientequality #humandatascience #lifesciences
-
Join us on Thursday, September 19 at the #RAPSConvergence for “Empowering Global Regulatory Affairs Professionals with Automated Surveillance Solutions”. Presenters Michael King and Bridget Wiseman will delve into the challenges and solutions for monitoring the ever-evolving landscape of global regulations and standards. Don’t miss this opportunity to stay ahead in #RegulatoryAffairs. https://bit.ly/4cKumPz #RAPS2024